NCT07123558Not yet recruiting
Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men
Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men - A Danish Prospective Study
Source: ClinicalTrials.gov · Last updated 14 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The incidence of anal cancer is increasing, particularly among high-risk groups such as men who have sex with men (MSM), especially those living with HIV. The lack of comprehensive screening programs results in delayed diagnosis and higher mortality. This project aims to establish a screening program for anal cancer in high-risk populations, with a specific focus on those most at risk. Using a prospective study design, the project will assess the effectiveness of early detection and prevention strategies to potentially reduce cancer incidence and improve survival rates. If an HPV-based screening method proves effective, it would serve as a potential implemention for high-risk groups in Denmark, further enhancing early detection and prevention efforts. This study represents the first large-scale, prospective screening initiative for anal cancer in Denmark,specifically targeting MSM. It introduces a novel approach to cancer prevention in this population by building on research in other cancers and adapting it to anal cancer and its specific risk factors. The project is a collaboration between clinical practitioners and academic researchers, ensuring that practical clinical insights guide the research and that research findings are rapidly translated into clinical practice. This partnership will enhance both the quality of the research and its direct application in healthcare. The project is expected to lead to earlier diagnosis of anal cancer, reduced morbidity and mortality among high-risk populations, and the establishment of a screening model that can be applied nationwide. This could significantly reduce the overall healthcare burden associated with late-stage anal cancer and improve patient outcomes across Denmark.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- First submitted
- 11 Jul 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Bispebjerg Hospital
- Diseases
- HIV
- NCT number
- NCT07123558
What you commit to
- Study type: Interventional
- Planned participants: 700
- From 1 Nov 2025 to the primary completion date, 31 Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous anal cancer
Other illness
- Inflammatory bowel disease
- Other known immunosuppressive disorder than HIV
Other
- Rectum extirpation (of any cause)
- Unwilling to have HRA performed
- Inability and unwillingness to give informed consent
- No sex with men
Who the study is looking for
- MSM with HIV
- HIV-negative MSMonPrEP
- Age \>=35 years
- Written and orally informed consent in English or Danish
Age in the registry: 35 years to - · Sex: Male · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.